Chandler Robinson
Chief Executive Officer, Director · Monopar Therapeutics
- 2024
- Oct 2, 2026
- 9
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Chandler Robinson files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Kim R. Tsuchimoto - $911K in MNPR purchases and sales in the last 12 months
- Raymond Anderson - $703K in MNPR purchases and sales in the last 12 months
- Christopher M. Starr - $659K in MNPR purchases and sales in the last 12 months
- Patrice Rioux - $111 in MNPR purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Chandler Robinson?
Chandler Robinson is a corporate insider, tracked as Chief Executive Officer, Director of Monopar Therapeutics (MNPR). InsiderAlpha holds 9 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Chandler Robinson submitted recently?
2 primary Form 4 filings in the last 90 days, covering 1 company.
Has Chandler Robinson been buying or selling stock?
Recorded transactions: 0 open-market purchases and 5 open-market sales ($3.23M) across all tracked filings.
